Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | £55,044 | £55,199 | £59,587 | £72,768 |
| % Growth | -0.3% | -7.4% | -18.1% | – |
| Cost of Goods Sold | £29,914 | £25,462 | £26,896 | £23,814 |
| Gross Profit | £25,130 | £29,737 | £32,691 | £48,954 |
| % Margin | 45.7% | 53.9% | 54.9% | 67.3% |
| R&D Expenses | £15,377 | £22,900 | £20,121 | £15,659 |
| G&A Expenses | £19,086 | £22,790 | £25,179 | £20,828 |
| SG&A Expenses | £38,288 | £42,381 | £48,884 | £46,832 |
| Sales & Mktg Exp. | £19,202 | £19,591 | £23,705 | £26,004 |
| Other Operating Expenses | £970 | -£287 | £3,894 | -£536 |
| Operating Expenses | £54,635 | £64,994 | £72,899 | £61,955 |
| Operating Income | -£29,505 | -£35,257 | -£34,851 | -£13,001 |
| % Margin | -53.6% | -63.9% | -58.5% | -17.9% |
| Other Income/Exp. Net | -£10,939 | -£3,909 | -£7,771 | -£396 |
| Pre-Tax Income | -£40,444 | -£39,166 | -£42,622 | -£13,397 |
| Tax Expense | -£312 | £1,050 | £1,305 | £1,119 |
| Net Income | -£40,132 | -£40,216 | -£43,071 | -£13,776 |
| % Margin | -72.9% | -72.9% | -72.3% | -18.9% |
| EPS | -0.008 | -0.011 | -0.064 | -0.021 |
| % Growth | 21.5% | 83.4% | -200.5% | – |
| EPS Diluted | -0.008 | -0.011 | -0.064 | -0.021 |
| Weighted Avg Shares Out | 4,766,440 | 3,743,332 | 669,844 | 643,017 |
| Weighted Avg Shares Out Dil | 4,766,440 | 3,743,332 | 670,355 | 642,990 |
| Supplemental Information | – | – | – | – |
| Interest Income | £382 | £285 | £329 | £257 |
| Interest Expense | £6,843 | £3,877 | £2,441 | £541 |
| Depreciation & Amortization | £4,172 | £4,319 | £4,224 | £4,166 |
| EBITDA | -£29,429 | -£30,740 | -£36,240 | -£8,690 |
| % Margin | -53.5% | -55.7% | -60.8% | -11.9% |